We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Zeynep Eroglu

Zeynep Eroglu MD

Medical Oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center; Assistant Professor, Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida
Dr. Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Her clinical focus is on treating patients with advanced melanoma and other skin cancers, including basal cell carcinoma and Merkel cell carcinoma, and participating in clinical trials. Dr. Eroglu’s research interests are translational and clinical research in targeted therapies and combination immunotherapeutics for melanoma and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma. 

Recent Contributions to PracticeUpdate:

  1. Potential Detrimental Effect of Antibiotics on Clinical Outcomes in the Setting of Immune-Checkpoint Blockade
  2. DCE-MRI Perfusion Predicts Pseudoprogression in Metastatic Melanoma Treated With Immunotherapy
  3. The Potential Development of PD-L1 as a Biomarker in Advanced Melanoma
  4. An Open-Source Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Melanoma
  5. Neoadjuvant Ipilimumab + Nivolumab for Primary or In Transit Melanoma
  6. Real-World Survival of Patients With Advanced BRAF V600–Mutated Melanoma Treated With Front-Line BRAF/MEK Inhibitors, Anti–PD-1 Antibodies, or Nivolumab/Ipilimumab
  7. Improved 5-Year Outcomes With Nivolumab Plus Ipilimumab in Advanced Melanoma
  8. Targeted Therapy Responses in Advanced Melanoma With Rare BRAF Mutations
  9. No Survival Benefit for Complete Lymph Node Dissection in Sentinel Node-Positive Melanoma
  10. Dabrafenib, Trametinib, and Pembrolizumab Prolong PFS in BRAF-Mutant Melanoma

Most Read This Week

Recently Updated